Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Gains from Investment Securities (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Gains from Investment Securities data on record, last reported at $196561.0 in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 214.92% year-over-year to $196561.0; the TTM value through Dec 2025 reached $196561.0, up 214.92%, while the annual FY2025 figure was $61410.0, 111.61% up from the prior year.
  • Gains from Investment Securities reached $196561.0 in Q4 2025 per INM's latest filing, up from $1054.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $971494.0 in Q4 2023 and bottomed at -$12307.0 in Q4 2022.
  • Average Gains from Investment Securities over 5 years is $122679.2, with a median of $61410.0 recorded in 2025.
  • The widest YoY moves for Gains from Investment Securities: up 7993.83% in 2023, down 145.85% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at -$6030.0 in 2021, then crashed by 104.1% to -$12307.0 in 2022, then surged by 7993.83% to $971494.0 in 2023, then plummeted by 93.58% to $62416.0 in 2024, then surged by 214.92% to $196561.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $196561.0 in Q4 2025, $1054.0 in Q3 2025, and $61410.0 in Q2 2025.